Skip to content Skip to sidebar Skip to footer
Subscribe Now
Weekly Snapshot
PharmaShots Weekly Snapshots (Jun 07, 2025 – Jul 11, 2025)   
This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, M&A, and Biosimilars. Check out our full report below:   PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy   Read More: PulseSight Therapeutics  BioAtla Presents Preliminary P-I Trial Data of BA3182 in Patients with…
July 11, 20250Comments
Merck Animal Health
News
FDA Approves Merck Animal Health’s Bravecto Quantum to Treat and Protect Dogs from Fleas and Ticks
Shots: The US FDA has approved Bravecto Quantum (Fluralaner for Extended-Release Injectable Suspension), a once-yearly injectable for flea and tick protection in dogs, will be available in U.S. veterinary clinics by Aug, 2025 Bravecto Quantum kills adult fleas and controls flea and tick infestations (Ixodes scapularis, Dermacentor variabilis, Rhipicephalus sanguineus) for 12 mos., and Amblyomma…
July 11, 20250Comments
Merck new
News
Merck NDA for Investigational HIV-1 Two-Drug Regimen DOR/ISL Accepted by US FDA
Shots: The US FDA accepted Merck’s NDA for once-daily oral doravirine/islatravir (DOR/ISL) for virologically suppressed HIV-1 adults; PDUFA target action date: Apr 28, 2026 DOR/ISL showed non-inferiority to bART in open-label P-III MK-8591A-051 and to BIC/FTC/TAF (50mg/200mg/25mg) in P-III MK-8591A-052 at Week 48; the safety profile was generally comparable in the P-III MK-8591A-051 study The…
July 11, 20250Comments
MAGAZINE
PharmaShots Magazine-July-2025 Edition
Regenerative medicine holds a promising potential in addressing unmet medical needs and bridging the gaps in healthcare. Regenerative medicine aims to provide innovative ways to repair, rejuvenate, and replace damaged tissues and organs. Regenerative medicine is widely explored in clinical settings as cellular therapies, extracellular vesicle therapies, immune cellular therapies, and tissue-engineered grafts to prevent…
July 10, 20250Comments
News
BeOne Medicines’ Tevimbra Receives the EC Approval for Nasopharyngeal Carcinoma
Shots: The EC has approved Tevimbra (tislelizumab) + gemcitabine & cisplatin for 1L treatment of adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy Approval was based on P-III (RATIONALE-309) trial assessing Tevimbra + gemcitabine & cisplatin vs PBO + gemcitabine & cisplatin in 263 treatment-naïve NPC pts Trial…
July 10, 20250Comments